Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard- dose imatinib: 2-year follow-up data from START-R

Philippe Rousselot,Thierry Facon,R. Paquette,Eric Bleickardt,David Dejardin,H. Kantarjian

Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard- dose imatinib: 2-year follow-up data from START-R

2008

Philippe Rousselot
Thierry Facon
R. Paquette
Eric Bleickardt
David Dejardin
H. Kantarjian

7012 Background: Resistance to imatinib is a well-recognized problem in CML-CP. Dasatinib is 325-fold more potent than imatinib against BCR-ABL in vitro is effective in imatinib-resistant CML patie...

Keywords:

Oncology
Pathology
Chronic phase CML
Chronic myelogenous leukemia
Internal medicine
Imatinib
Medicine
Dasatinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations